August 9, 2026

Newsletter

The European Post

Policy • Diplomacy • Strategic Insight

LATEST
New EU Gas Market Rules Take Effect With Consumer SafeguardsDeforestation Regulation Holds Its December Deadline Despite CutsDigital Omnibus Delays Europe’s High-Risk AI Deadline to 2027Europe’s Schools Confront a Widening Basic Skills GapRule of Law Report Finds Progress but Trust Still LagsIRIS2 Gains 66 Satellites as Brussels Signs the Rollout DealNature Restoration Plans Come Due as Member States Race a DeadlineECB Rates Hold at 2.25 Percent as Frankfurt Waits on the DataEU Budget Talks Turn to Cohesion as Ireland Takes OverWildfire Response Stretches Europe’s Emergency Fleet ThinCan Europe’s Quantum Plan Match Its Big Ambitions?Armenia Edges West as Moscow’s Grip Slips AwayEurope Inherits the World’s Aid Bill It Cannot Fully PayAir Passenger Rights Get Their First Overhaul in Two DecadesErasmus Opens a 5 Billion Euro Round for Skills and MobilityCeuta Crisis Pushes the EU Toward Faster Migrant ReturnsBulky Parcels Face a Packaging Crackdown From August 12Can Europe Build Its Drone Wall Before 2030 Arrives?Indonesia’s Trade Deal With Europe Nears Its Final SignatureEurope Leans on Beijing to Keep Climate Talks Alive Before AntalyaNew EU Gas Market Rules Take Effect With Consumer SafeguardsDeforestation Regulation Holds Its December Deadline Despite CutsDigital Omnibus Delays Europe’s High-Risk AI Deadline to 2027Europe’s Schools Confront a Widening Basic Skills GapRule of Law Report Finds Progress but Trust Still LagsIRIS2 Gains 66 Satellites as Brussels Signs the Rollout DealNature Restoration Plans Come Due as Member States Race a DeadlineECB Rates Hold at 2.25 Percent as Frankfurt Waits on the DataEU Budget Talks Turn to Cohesion as Ireland Takes OverWildfire Response Stretches Europe’s Emergency Fleet ThinCan Europe’s Quantum Plan Match Its Big Ambitions?Armenia Edges West as Moscow’s Grip Slips AwayEurope Inherits the World’s Aid Bill It Cannot Fully PayAir Passenger Rights Get Their First Overhaul in Two DecadesErasmus Opens a 5 Billion Euro Round for Skills and MobilityCeuta Crisis Pushes the EU Toward Faster Migrant ReturnsBulky Parcels Face a Packaging Crackdown From August 12Can Europe Build Its Drone Wall Before 2030 Arrives?Indonesia’s Trade Deal With Europe Nears Its Final SignatureEurope Leans on Beijing to Keep Climate Talks Alive Before Antalya
August 9, 2026

Newsletter

The European Post

Policy • Diplomacy • Strategic Insight

LATEST
New EU Gas Market Rules Take Effect With Consumer SafeguardsDeforestation Regulation Holds Its December Deadline Despite CutsDigital Omnibus Delays Europe’s High-Risk AI Deadline to 2027Europe’s Schools Confront a Widening Basic Skills GapRule of Law Report Finds Progress but Trust Still LagsIRIS2 Gains 66 Satellites as Brussels Signs the Rollout DealNature Restoration Plans Come Due as Member States Race a DeadlineECB Rates Hold at 2.25 Percent as Frankfurt Waits on the DataEU Budget Talks Turn to Cohesion as Ireland Takes OverWildfire Response Stretches Europe’s Emergency Fleet ThinCan Europe’s Quantum Plan Match Its Big Ambitions?Armenia Edges West as Moscow’s Grip Slips AwayEurope Inherits the World’s Aid Bill It Cannot Fully PayAir Passenger Rights Get Their First Overhaul in Two DecadesErasmus Opens a 5 Billion Euro Round for Skills and MobilityCeuta Crisis Pushes the EU Toward Faster Migrant ReturnsBulky Parcels Face a Packaging Crackdown From August 12Can Europe Build Its Drone Wall Before 2030 Arrives?Indonesia’s Trade Deal With Europe Nears Its Final SignatureEurope Leans on Beijing to Keep Climate Talks Alive Before AntalyaNew EU Gas Market Rules Take Effect With Consumer SafeguardsDeforestation Regulation Holds Its December Deadline Despite CutsDigital Omnibus Delays Europe’s High-Risk AI Deadline to 2027Europe’s Schools Confront a Widening Basic Skills GapRule of Law Report Finds Progress but Trust Still LagsIRIS2 Gains 66 Satellites as Brussels Signs the Rollout DealNature Restoration Plans Come Due as Member States Race a DeadlineECB Rates Hold at 2.25 Percent as Frankfurt Waits on the DataEU Budget Talks Turn to Cohesion as Ireland Takes OverWildfire Response Stretches Europe’s Emergency Fleet ThinCan Europe’s Quantum Plan Match Its Big Ambitions?Armenia Edges West as Moscow’s Grip Slips AwayEurope Inherits the World’s Aid Bill It Cannot Fully PayAir Passenger Rights Get Their First Overhaul in Two DecadesErasmus Opens a 5 Billion Euro Round for Skills and MobilityCeuta Crisis Pushes the EU Toward Faster Migrant ReturnsBulky Parcels Face a Packaging Crackdown From August 12Can Europe Build Its Drone Wall Before 2030 Arrives?Indonesia’s Trade Deal With Europe Nears Its Final SignatureEurope Leans on Beijing to Keep Climate Talks Alive Before Antalya

Lung Drug Leads A Wave Of Eight Medicines Cleared In Europe

Jóhannes Guðnason
Legislative Affairs Editor, Health and Wellbeing

Ingelheim: From the Rhineland town that houses one of Europe’s oldest drugmakers, a treatment for a cruel and poorly understood lung disease has cleared its most important regulatory test. The European Medicines Agency’s human medicines committee recommended eight new products for approval at its latest monthly meeting, and among them was nerandomilast, a therapy aimed at idiopathic and progressive pulmonary fibrosis, conditions in which lung tissue scars relentlessly until breathing fails.

Pulmonary fibrosis has long frustrated doctors. Only a handful of medicines slow it, none stop it, and patients often face a prognosis grimmer than many cancers. A positive opinion for a new agent in this field is therefore more than a routine line in a committee bulletin. It signals the first genuinely new option in years for a group of patients who have had little to hope for, and it explains why pulmonary specialists across the continent have followed the file so closely.

The committee’s verdict came alongside seven other recommendations and more than a dozen extensions to medicines already on the market. The agency’s opinions are scientific advice rather than the final word: each now passes to the European Commission, which issues the legally binding marketing authorisation valid across all member states. That last step is usually a formality, but it is the moment a drug actually becomes available to prescribe, and national pricing negotiations then determine how quickly patients in each country can reach it.

The same meeting underlined how fast the treatment of obesity is reshaping European medicine. The committee backed an extension that would allow a widely used weight-management injection to be taken as a daily tablet, the first oral version of its class cleared for that purpose. For a field dominated by weekly injections, an oral formulation could widen access considerably, particularly for patients reluctant to inject or living far from clinics. It also sharpens the budgetary dilemma facing health systems already straining to fund demand for these drugs.

Behind the headline names sat the quieter business of the regulator: a conditional authorisation granted on the strength of early but promising data, recommendations for treatments of rare conditions, and the steady accumulation of indication extensions that expand who an existing medicine may help. None of it makes for dramatic reading, yet this monthly rhythm is how Europe decides what its doctors may offer and on what evidence.

For all the talk of artificial intelligence and accelerated pathways, the process on display remains deliberately conservative. Committees weigh trial results, demand follow-up studies and accept that some approvals carry conditions. The reward for that caution is public trust in the verdict. For a patient in a fibrosis clinic waiting on the Commission’s signature, the machinery may feel slow, but the destination, a new medicine within reach, is the one that counts.

Comments